BioSpace News Archive

The California School of Professional Psychology (CSPP) at Alliant International University’s clinical psychology Psy.D. degree program at its Sacramento campus has just earned 10 years re-accreditation by the American Psychological Association (APA)— the longest period of re-accreditation offered by the association.

Today eHealth, Inc. (NASDAQ: EHTH) (eHealth.com) announced that Dale B. Wolf has been appointed an independent director to the company’s Board of Directors.

Cellular Biomedicine Group Inc. (NASDAQ: CBMG) (“CBMG” or the “Company”), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today reported its financial results and business highlights for the second quarter and six months ended June 30, 2019.

Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced financial and operating results for the second quarter ended June 30, 2019.

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced the appointment of Rafael G. Amado, M.D., as Executive Vice President of Research and Development and Chief Medical Officer

Based in the firm’s New York office, Dr. Benjamin will focus on the oncology sector.

Will Reduce Medicare Costs in Maryland by at least $35 Million

The Hyundai Hope On Wheels non-profit embarks on a nationwide tour this Summer to award new grants for pediatric cancer, surpassing $160 million in lifetime funding for research.

Serimmune today announced key appointments to strengthen its executive team. Noah Nasser has been appointed chief executive officer and Bill Welch, venture partner at Illumina Ventures, has been appointed to the company’s board of directors

Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that Andy Boral, M.D., Ph.D., Blueprint Medicines’ Chief Medical Officer, will present a company overview at the 2019 Wedbush PacGrow Healthcare Conference in New York,